Comparison
LL-37 vs. Teduglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
597562-32-8
197922-42-2
Molecular weight
4493.33 g/mol
3752.13 g/mol
Half-life
no data
no data
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESno data
Mechanism of action
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
2
of which in humans
1
2
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
0
2
Legal status
Full entries
Frequently asked questions
- What is the difference between LL-37 and Teduglutid?
- LL-37 is classified as "Research other", while Teduglutid is classified as "Research other". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Teduglutid?
- The highest available evidence level is "Human trial" for LL-37 and "Human RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Teduglutid in Germany and the United States?
- Germany: LL-37 — Research only, Teduglutid — Prescription. United States: LL-37 — Research only, Teduglutid — Prescription. These are factual summaries with source and review date on the individual pages.